Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Norgine

More Like This

PR Newswire associated0

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

ACOUSIA THERAPEUTICS REACHES 50% PATIENT ENROLLMENT MILESTONE IN PHASE 2 PROHEAR STUDY

ACOUSIA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 PROHEAR STUDY EVALUATING ACOU085 (INN: BIMOKALNER) FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY

Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease